Small molecule inhibitors of EZH2, such as EPZ-6438 (tazemetostat), can decrease the trimethylation of H3K27, leading to re-expression of silenced genes involved in growth inhibition and apoptosis.189 Early-phase clinical trials are evaluating the safety and efficacy of EZH2 inhibitors in solid tumors, including CRC.190. Here, EZH2 is linked to colorectal carcinoma.